You are here: Industry Insights > RoActemra

News List

EMA recommends RoActemra in adults with severe COVID-19 EuropeanPharmaceuticalReview
December 10, 2021
The European Medicines Agency (EMA)’s human medicines committee (CHMP) recommends extending RoActemra’s indication to include COVID-19 patients receiving systemic treatment.
New products to drive systemic sclerosis market to $1.8 bn by 2030: GlobalData expresspharma
June 21, 2021
GlobalData expects Ofev and Actemra/RoActemra to reach peak global sales of $508.8 million in 2025 and $163.2 million in 2024, respectively.
Novartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche's Actemra/RoActemra® worldpharmanews
May 08, 2021
Novartis has signed an initial agreement with Roche to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient (API) for Roche's Actemra/RoActemra® (tocilizumab), a treatment for rheumatoid ...
Actemra/RoActemra, arthritis drug from Roche fails to meet primary endpoint of COVID-19 trial expresspharma
July 30, 2020
The COVACTA study did not meet its primary endpoint of improved clinical status in hospitalised adult patients with severe COVID-19 associated pneumonia or identify any new safety signals for Actemra/RoActemra.
EU secures potential COVID-19 drugs from Roche, Germany’s Merck – source expresspharma
July 10, 2020
The deals cover Roche’s arthritis drug RoActemra and Merck’s multiple sclerosis drug Rebif - both seen as potential COVID-19 therapies - and will secure supplies for any of the 27 European Union member states wanting to buy them.
Roche to begin Covid-19 pneumonia trial with Actemra/RoActemra plus remdesivir pharmaceutical-business-review
June 02, 2020
Roche has announced the commencement of phase III clinical study of Actemra/RoActemra plus remdesivir in hospitalised patients with severe Covid-19 pneumonia.
Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patien worldpharmanews
June 01, 2020
Roche announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir ...
Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia worldpharmanews
March 23, 2020
Roche is working with the Food & Drug Administration (FDA) to initiate a randomised, double-blind, placebo-controlled Phase III clinical trial in collaboration ...
Roche to start Phase III trial of Actemra in Covid-19 patients pharmaceutical-technology
March 20, 2020
Roche has collaborated with the US Food and Drug Administration (FDA) to conduct a Phase III clinical trial of Actemra/RoActemra (tocilizumab) in hospitalised adults with severe Covid-19 pneumonia.